Weight gain, metabolic disturbances, and physical health care in a Brazilian sample of outpatients with schizophrenia

Neuropsychiatric Disease and Treatment

Volumn 9, Issue 1, 2012, Pages 133-138

  Gordon, Pedro Caldana ^a   Xavier, Josefa Cynara ^a   Louzã, Mario Rodrigues ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antipsychotic drugs; Cardiovascular disorders; Obesity; Psychosis; Public health

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; CHOLESTEROL; CLOZAPINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MOOD STABILIZER; NEUROLEPTIC AGENT; THYROID HORMONE; TRIACYLGLYCEROL; VALPROIC ACID;

ADULT; AGE; ARTICLE; BODY MASS; BRAZIL; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC PATIENT; CROSS-SECTIONAL STUDY; DEPRESSION; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE DURATION; DRUG USE; DYSLIPIDEMIA; EPILEPSY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HEALTH STATUS; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; METABOLIC SYNDROME X; OBESITY; OUTPATIENT; PREVALENCE; SCHIZOPHRENIA; SEDENTARY LIFESTYLE; SEIZURE; SMOKING; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST HIP RATIO; WEIGHT GAIN;

EID: 84872859043     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S37019     Document Type: Article

References (31)

1. Leucht S, Burkard T, Henderson J, Maj M, Sartorius N. Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand. 2007;116(5):317-333.
2. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia. Is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007;64(10):1123-1131.
3. Barnett AH, Mackin P, Chaudhry I, etal. Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. J Psychopharmacol. 2007;21(4):357-373.
4. Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry. 1997;171:502-508.
5. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005;150(6): 1115-1121.
6. Tran E, Rouillon F, Loze JY, etal. Cancer mortality in patients with schizophrenia: an 11-year prospective cohort study. Cancer. 2009; 115(15):3555-3562.
7. Meyer JM, Davis VG, Goff DC, etal. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res. 2008;101(1-3): 273-286.
8. Rummel-Kluge C, Komossa K, Schwarz S, etal. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010;123(2-3):225-233.
9. De Hert M, Correll CU, Bobes J, etal. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry. 2011;10(1):52-77.
10. Newcomer JW. Second generation (atypical) antipsychotics and metabolic effects. A comprehensive literature review. CNS Drugs. 2005;19(1):1-93.
11. Lieberman JA, Stroup TS, McEvoy JP, etal; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223.
12. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31-41.
13. De Hert M, Schreurs V, Sweers K, etal. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr Res. 2008;101(1-3):295-303.
14. Smith M, Hopkins D, Peveler RC, Holt RI, Woodward M, Ismail K. First-v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2008;192(6):406-411.
15. Daumit GL, Goff DC, Meyer JM, etal. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res. 2008;105(1-3):175-187.
16. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 4th ed (DSM-IV). Washington, DC: American Psychiatric Association; 1994.
17. Expert panel on detection evaluation and treatment of high blood cholesterol in adults. Executive summary of the third Report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in a adults (Adult treatment panel III). JAMA. 2001;285(19):2486-2497.
18. Grundy SM, Cleeman JI, Daniels SR, etal. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735-2752.
19. Majadas S, Olivares J, Galan J, Diez T. Prevalence of depression and its relationship with other clinical characteristics in a sample of patients with stable schizophrenia. Compr Psychiatry. 2012;53(2):145-151.
20. Gigante DP, Moura EC, Sardinha LM. Prevalence of overweight and obesity and associated factors, Brazil, 2006. Rev Saude Publica. 2009;43 Suppl 2:S83-S89.
21. Leitão-Azevedo CL, Guimarães LR, de Abreu MG, Gama CS, Lobato MI, Belmonte-de-Abreu PS. Increased dyslipidemia in schizophrenic outpatients using new generation antipsychotics. Rev Bras Psiquiatr. 2006;28(4):301-304.
22. Teixeira PJ, Rocha FL. The prevalence of metabolic syndrome among psychiatric inpatients in Brazil. Rev Bras Psiquiatr. 2007;29(4): 330-336.
23. Misawa F, Shimizu K, Fujii Y, etal. Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study. BMC Psychiatry. 2011;11:118.
24. Bakx JC, van den Hoogen HJ, Deurenberg P, van Doremalen J, van den Bosch WJ. Changes in serum total cholesterol levels over 18 years in a cohort of men and women: The Nijmegen Cohort Study. Prev Med. 2000;30(2):138-145.
25. Allison DB, Mentore JL, Heo M, etal. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156(11):1686-1696.
26. Millen BA, Campbell GM, Beasley CM. Weight changes over time in adults treated with the oral or depot formulations of olanzapine: a pooled analysis of 86 clinical trials. J Psychopharmacol. 2011;25(5): 639-645.
27. Padmavati R, McCreadie RG, Tirupati S. Low prevalence of obesity and metabolic syndrome in never-treated chronic schizophrenia. Schizophr Res. 2010;121(1-3):199-202.
28. De Hert M, Cohen D, Bobes J, etal. Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry. 2011;10(2):138-151.
29. Mitchell AJ, Delaffon V, Vancampfort D, Correll CU, De Hert M. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychol Med. 2012;42(1):125-147.
30. Ratliff JC, Palmese LB, Reutenauer EL, Liskov E, Grilo CM, Tek C. The effect of dietary and physical activity pattern on metabolic profile in individuals with schizophrenia: a cross-sectional study. Compr Psychiatry. 2012;53(7):1028-1033.
31. Vancampfort D, Probst M, Knapen J, Carraro A, De Hert M. Associations between sedentary behaviour and metabolic parameters in patients with schizophrenia. Psychiatry Res. Epub April 10, 2012.